MedTrace Logo

Study of PBF-999 in Solid Tumour Advanced Cancer

NCT03786484 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2023-01-26

No results posted yet for this study

Summary

Multicentric phase I (dose escalation plus expansion) clinical trial of PBF-999 in patients with immunotherapy naïve and pretreated solid tumors to evaluate the safety, tolerability and preliminary efficacy of the compound

Conditions

Interventions

DRUG

PBF-999

Phosphodiesterase 10 inhibitor (PDE10i)

Sponsors & Collaborators

  • Vall d'Hebron institute of oncology (VHIO), Catalan institute of oncology (Hospitalet) (ICO)

    collaborator UNKNOWN

  • Palobiofarma SL

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03786484 on ClinicalTrials.gov